Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview at the following investment conferences:

-- Deutsche Bank's 33rd Annual Healthcare Conference at the

InterContinental Hotel in Boston on Tuesday, May 6, 2008 at 2:10pm

Eastern Time (11:10am Pacific Time)

-- Bank of America's 2008 Healthcare Conference at the Four Seasons Hotel

in Las Vegas on Wednesday, May 14, 2008 at 4:00pm Pacific Time (7:00pm

Eastern Time)

-- JMP Securities' Seventh Annual Research Conference at the Ritz-Carlton

Hotel in San Francisco on Wednesday, May 21, 2008 at 12:00pm Pacific

Time (3:00pm Eastern Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentations, click on the Investor Relations tab the link entitled "Events and Presentations" on the left side of the screen. A replay of each webcast will available approximately one hour after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in developme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
3. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
4. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... In the same week that state senators in Wisconsin ... to include ethanol, policymakers in another Midwestern state were ... , ,Agri-business giant Louis Dreyfus Corp. announced it ... northern Indiana, where it plans to crush nearly 50 ...
... company in central Wisconsin has announced its plans ... offerings of high-speed Internet and voice over IP services. ... serves about 28,000 customers. CEO Douglas Wenzlaff told reporters ... Madison and Eau Claire. Its existing base is in ...
Cached Biology Technology:Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 2Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 3
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... in those green coffee bean dietary supplements often touted ... obese laboratory mice fed a high-fat diet when given at ... in ACS, Journal of Agricultural and Food Chemistry . ... fat in the liver. Vance Matthews, Kevin Croft ...
... 2013: A new study presented today at EULAR 2013, ... shows that one in eight patients at risk of ... over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat ... NSAID users, over one-third had taken the medication for ...
... show ways in which we can markedly improve drug targeting ... imaging techniques. In real time and in three dimensions, ... active cancer cells respond to a particular drug. They can ... to administer drugs. Finally, using preclinical models of the disease, ...
Cached Biology News:Patients use OTC NSAIDs even when they have a high risk of serious side effects 2Nanotechnology helps track and improve drug action in pancreatic cancer 2
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Penicillin-Streptomycin liquid...
...
Biology Products: